Improving quality of life after treatment for rectal cancer

Affiliations

Comment

Geerard Beets. Lancet. 2017.

. 2017 Jul 29;390(10093):432-434.

doi: 10.1016/S0140-6736(17)31545-3. Epub 2017 Jun 7.

¹ The Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands; Maastricht University, Maastricht, Netherland. Electronic address: g.beets@nki.nl.

No abstract available

Comment on

Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A. Rullier E, et al. Lancet. 2017 Jul 29;390(10093):469-479. doi: 10.1016/S0140-6736(17)31056-5. Epub 2017 Jun 7. Lancet. 2017. PMID: 28601342 Clinical Trial.